TALQUETAMAB 40 MG INJECTION
TALVEY (talquetamab-tgvs) is a bispecific GPRC5D-directed CD3 T-cell engager. It is a humanized IgG4 proline, alanine, alanine (IgG4-PAA)-based bispecific antibody produced by Chinese hamster ovary (CHO) cells using recombinant DNA technology. Talquetamab-tgvs consists of an anti-GPRC5D heavy chain and light chain and an anti-CD3 heavy chain and light chain with two interchain disulfide bonds connecting the two arms. The molecular weight of talquetamab-tgvs is 147 kDa. TALVEY™ (talquetamab-tgvs) injection is a sterile, preservative-free colorless to light yellow solution supplied in a single-dose vial for subcutaneous administration.
TALVEY (talquetamab-tgvs) , 3 mg/1.5 mL (2 mg/mL) in a single-dose vial (3) • 40 mg/mL in a single-dose vial (3)
Please click here- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf
TALVEY (talquetamab-tgvs) is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
